1
|
van der Veer WM, Bloemen MC, Ulrich MM,
Molema G, Van Zuijlen PP, Middelkoop E and Niessen FB: Potential
cellular and molecular causes of hypertrophic scar formation.
Burns. 35:15–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Rhett JM, Ghatnekar GS, Palatinus JA,
O'Quinn M, Yost MJ and Gourdie RG: Novel therapies for scar
reduction and regenerative healing of skin wounds. Trends
Biotechnol. 26:173–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Sun Q, Guo S, Wang CC, Sun X, Wang D, Xu
N, Jin SF and Li KZ: Cross-talk between TGF-β/Smad pathway and
Wnt/β-catenin pathway in pathological scar formation. Int J Clin
Exp Pathol. 8:7631–7639. 2015.PubMed/NCBI
|
4
|
Huang LP, Mao Z, Zhang L, Liu XX, Huang C
and Jia ZS: Screening of differentially expressed genes in
pathological scar tissues using expression microarray. Genet Mol
Res. 14:10743–10751. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lamouille S, Connolly E, Smyth JW, Akhurst
RJ and Derynck R: TGF-β-induced activation of mTOR complex 2 drives
epithelial-mesenchymal transition and cell invasion. J Cell Sci.
125:1259–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ghazizadeh M, Tosa M, Shimizu H, Hyakusoku
H and Kawanami O: Functional implications of the IL-6 signaling
pathway in keloid pathogenesis. J Invest Dermatol. 127:98–105.
2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ishihara H, Yoshimoto H, Fujioka M,
Murakami R, Hirano A, Fujii T, Ohtsuru A, Namba H and Yamashita S:
Keloid fibroblasts resist ceramide-induced apoptosis by
overexpression of insulin-like growth factor I receptor. J Invest
Dermatol. 115:1065–1071. 2000. View Article : Google Scholar : PubMed/NCBI
|
9
|
van den Bogaerdt AJ, van der Veen VC, Van
Zuijlen PP, Reijnen L, Verkerk M, Bank RA, Middelkoop E and Ulrich
MM: Collagen cross-linking by adipose-derived mesenchymal stromal
cells and scar-derived mesenchymal cells: Are mesenchymal stromal
cells involved in scar formation? Wound Repair Regen. 17:548–558.
2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chen W, Fu X, Sun T, Sun X, Zhao Z and
Sheng Z: Change of gene expression of transforming growth
factor-beta1, Smad 2 and Smad 3 in hypertrophic scars skins.
Zhonghua Wai Ke Za Zhi. 40:17–19. 2002.(In Chinese). PubMed/NCBI
|
11
|
Teofoli P, Barduagni S, Ribuffo M,
Campanella A, De Pita' O and Puddu P: Expression of Bcl-2, p53,
c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J
Dermatol Sci. 22:31–37. 1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kleinerman R, Kilmer SL and Chotzen VA:
Mitomycin C in the treatment of keloids: A case and review. J Drugs
Dermatol. 12:701–703. 2013.PubMed/NCBI
|
13
|
Matsuoka T and Yashiro M: The role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gomez-Pinillos A and Ferrari AC: mTOR
signaling pathway and mTOR inhibitors in cancer therapy. Hematol
Oncol Clin North Am. 26:483–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Xavier S, Niranjan T, Krick S, Zhang T, Ju
W, Shaw AS, Schiffer M and Böttinger EP: TbetaRI independently
activates Smad- and CD2AP-dependent pathways in podocytes. J Am Soc
Nephrol. 20:2127–2137. 2009. View Article : Google Scholar : PubMed/NCBI
|